France's DBV Technologies 2025 net loss widens, operating income rises

DBV Technologies SA

26/03/2026 21:17

Overview

France biopharmaceutical developer's 2025 operating income rose, while net loss widened year-over-year

R&D expenses increased due to pre-commercial inventory and clinical trial costs for VIASKIN Peanut Patch

Outlook

DBV says cash position sufficient to fund operations into Q2 2027, based on current plans

Result Drivers

R&D SPENDING - Higher R&D expenses driven by pre-commercial inventory build-up and clinical trial costs for VIASKIN Peanut Patch

Company press release: ID:nGNE9nn1KT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$147 mln
FY Operating Income
$5.6 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dbv Technologies SA is €5.25, about 48.7% above its March 26 closing price of €3.53

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)